Drug has different mechanism of action than existing injectables ...

A new study reveals experimental drug XL20 crosses the blood-brain barrier to stop toxic TDP-43 clumping in ALS.

AstraZeneca announces positive results from MULBERRY phase III trial of efzimfotase alfa, an investigational enzyme replacement therapy: Cambridge, UK Tuesday, June 30, 2026, 11:0 ...

More than 100 government officials, investors, industry experts and technology founders gathered here Monday for the second ...

Company Moves From Filed IP Protection to Live Distribution, Positioning Digitalage for Initial Revenue Activation in the Creator EconomyTEMECULA, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Hop-on, Inc ...

Stepping into the next phase of internet infrastructure requires recognizing that not all traffic should be treated equally ...

The Fourier pixel colored logo of ETH Zurich. The letter ‘E’ is roughly 1 millimeter tall on the camera. Credit: Glauser YM, ...

As the Principal Scientist at Abu Dhabi-based QRDC, he has been paving the way for newer advancements in quantum photonics ...

To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.

Soft robotics continues to push beyond the constraints of rigid mechanisms, offering adaptable solutions for grasping, ...

There's a particular moment that most travelers and newcomers can pinpoint almost exactly. You've been in a city for a day or ...

The FDA is reviewing full approval bids for the Duchenne therapies Amondys 45 and Vyondys 53, with decisions expected by ...